Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
News published by Savara Inc. concerning molgramostim nebulizer solution, a novel investigational inhaled biologic, administered via an optimized eFlow® Technology nebulizer.